The U.S. Food and Drug Administration (FDA) is convening an advisory panel to determine whether to add a ‘black box’ warning to antidepressants regarding their use during pregnancy. The panel is divided, with some critics of psychiatry arguing that these medications can harm a developing fetus, while other experts maintain that antidepressants are essential for managing mental health conditions during pregnancy. The debate highlights the complex balance between potential risks and therapeutic benefits for pregnant women.